Imaging the brain in Covid-19 patients using PET and MRI technology
Pilot Study for Simultaneous PET-MR Imaging of Covid-19 Associated Neurological Complications Using a Brain Dedicated PET Insert
This study is testing a new way to take pictures of the brain using special technology to see how Covid-19 might affect brain function in people who have had the virus and those who haven't.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 21 Years and up |
| Sex | All |
| Sponsor | Stanford University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Palo Alto, California) |
| Trial ID | NCT04954248 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to evaluate the feasibility of a specialized brain-dedicated PET insert for an MR scanner, allowing for simultaneous PET and MR imaging to assess brain metabolism and perfusion in individuals with and without a history of Covid-19. The study will recruit 10 participants, including 5 who are currently Covid-19 negative and 5 who were previously positive within the last 180 days. The focus is on establishing an imaging protocol that combines functional information from PET with anatomical data from MRI, using an FDA-approved radiotracer. This is a non-randomized, non-treatment study primarily assessing the technology rather than treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 21 and older who are healthy enough to undergo imaging and have proof of Covid-19 testing within the specified timeframe.
Not a fit: Patients with a history of non-MRI compatible surgeries or implants, pregnant or nursing individuals, and those with allergic reactions to PET radiotracers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of brain changes associated with Covid-19, potentially leading to improved diagnostic protocols.
How similar studies have performed: While this approach is innovative, similar imaging techniques have shown promise in other contexts, but this specific application for Covid-19 is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Whole body radiation dose in the last year of less than 5000 mrem determined via subject verbal history reporting 2. Must be at least 21 years of age 3. Deemed healthy to endure duration of imaging study as confirmed via study PI 4. Proof of COVID-19 viral or antibody testing within the timeframe of \>20 days but \<=180 days prior to scan. Exclusion Criteria: 1. History of non-MRI compatible surgeries, implants, or activities 2. Pregnant or nursing 3. History of allergic reactions to PET radiotracers (via patient verbal report and /or medical record review.
Where this trial is running
Palo Alto, California
- Stanford University — Palo Alto, California, United States (Recruiting)
Study contacts
- Study coordinator: Marcus Lou
- Email: mlou002@stanford.edu
- Phone: 4158163957
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.